The genus Nocardia represents a subgroup of "aerobic actinomycetes" within the order Actinomycetales; they are gram-positive bacilli characterized by filamentous and branching morphology, formation of aerial mycelia in the environment and in culture, partial acid-fast stain, and resistance to lysozyme. 1 Since the initial isolation by Edmond Nocard more than a century ago, this genus currently contains 101 species (www.bacterio.net/Nocardia.html, accessed December 11, 2013). Due to the relatively inert metabolism and slow growth rates of these organisms, however, specific taxonomic placement of a Nocardia isolate based solely on phenotypic methods has been difficult and imprecise. 2, 3 As such, most clinical microbiology laboratories rarely attempt to identify Nocardia to species level. In recent years, however, Upon completion of this activity you will be able to:
molecular methods, such as nucleic acid hybridization techniques, restriction fragment length polymorphism, and gene sequencing analysis, have emerged as viable means for the identification and/or taxonomy of Nocardia in many research and clinical laboratories. [4] [5] [6] [7] [8] [9] These technical advances have led to new descriptions or taxonomic revisions of many Nocardia species. 10, 11 There are approximately 40 medically relevant Nocardia species, which can cause pulmonary, cutaneous, and disseminated infections. 1, 11 Most of these infections are opportunistic, being reported more frequently in patients with various degrees of deficiency in cellular immunity, such as those with AIDS and recipients of organ or hematopoietic stem cell transplant (HSCT). These patients carry an incidence of Nocardia infection at 140-to 340-fold higher than that of the general population. 12 Thus, empiric prophylaxis for Nocardia in these patients is important.
The new descriptions and taxonomic revisions necessitate periodic and large-scale analyses of clinical Nocardia strains for correlative studies for the clinical and microbiological features. In addition, the correlation between Nocardia taxa and particular antimicrobial susceptibility patterns implies that rapid and accurate species-level identification may aid timely initiation of effective empiric antimicrobial therapy. [13] [14] [15] [16] During the past decade, we have used the increasingly popular 16S ribosomal RNA (rRNA) gene sequencing approach to accurately and speedily identify clinical Nocardia strains. 17 Here we report clinical and microbiological analyses of 138 consecutive Nocardia strains isolated from 132 patients in Houston, Texas.
Materials and Methods

Study Setting and Patients
The Nocardia strains were consecutive (sporadic) isolates from June 2002 through December 2012 at the University of Texas M. D. Anderson Cancer Center, Houston, Texas. The institution is a comprehensive cancer center that had 500 beds in 2002, increasing to 590 beds in 2012. Nearly all patients with Nocardia isolates had a primary diagnosis of cancer. Anticancer chemotherapy often required use of indwelling central venous catheters (CVCs). Approximately two-thirds of patients were from the greater Houston area and other parts of Texas. Patients from other states and other countries usually stayed in Houston for extended periods for their cancer care. In view of the environmental origin of Nocardia, the climate in Houston included abundant rainfall (around 140 cm each year) and a warm temperature (monthly means of 12.4°C in the coldest January to 29.1°C in the warmest July and August).
Culture Methods
Blood cultures were performed using the BACTEC 9240 Plus aerobic/F bottles (BD Diagnostic Systems, Sparks, MD) and Isolator tubes (Wampole Laboratories, Princeton, NJ). BACTEC bottles were incubated for 7 days at 35°C with aeration in the automated system. Isolator tubes were incubated for 4 days at 35°C with 5% carbon dioxide, and these cultures allowed quantitation of bacterial colonies. Approximately 30,000 blood cultures were performed annually in the institution. Cultures of specimens from the respiratory tract (sputa, bronchial washings, bronchoalveolar lavages, etc) and other sources were set up to recover bacteria on sheep blood agar and chocolate agar plates and to recover fungi on Emmons Sabouraud dextrose agar and brain-heart infusion agar (all from BD Diagnostic Systems). The fungal culture plates were incubated at 35°C for up to 28 days. Cultures for acid-fast bacilli, from which Nocardia can be cultivated occasionally, were set up in Lowenstein-Jansen tubes and BacT/Alert MP liquid bottles (BioMerieux, Durham, NC) and incubated for up to 8 weeks. If the same Nocardia species was isolated sequentially from repeat sampling or from different sources of sampling within one admission of a patient, it was counted as one unique strain.
Species Identification
Initial recognition of Nocardia included chalky white colonies on culture plates, branching gram-positive bacilli, and positive partial acid-fast stain. These bacilli were further identified by sequencing a portion of the 16S rRNA gene as previously described. 17 Briefly, for DNA extraction, isolated colonies were suspended in a 100-μL extraction buffer (Prepman Ultra; Applied Biosystems, Carlsbad, CA), boiled for 10 minutes at 105°C, and centrifuged (8,000g for 10 minutes). Then, 1 μL of supernatant was used as a template in a 25-μL polymerase chain reaction, including activation of the enzyme (92°C for 2 minutes), 35 cycles of denaturation (95°C for 20 seconds), annealing (62°C for 20 seconds), and extension (72°C for 40 seconds), with the last extension at 72°C for 5 minutes. For most isolates, an approximately 600-base pair (bp) region corresponding to nucleotides 459 to 1,050 of Nocardia asteroides ATCC 19247 (GenBank accession DQ659898) was amplified using two universal bacterial primers: 5'-tgccagcagccgcggtaatac (forward) and 5'-cgctcgttgcgggacttaacc (reverse). For some isolates whose identity remained ambiguous after analysis of this amplicon, such as those of Nocardia veterana and Nocardia kruczakiae, additional amplification and sequencing of a more proximal approximately 600-bp region of the gene was performed. The primers were 5'-gcgtgcttaacacatgcaagtc (forward) and 5'-tcctcctgatatctgcgcattc (reverse), corresponding to nucleotides 13 to 659 of N asteroides ATCC 19247 (DQ659898). The two overlapping amplicons covered ~1,030 bp of the 16S gene to allow confident identification of all strains to species level in this study.
Bidirectional consensus sequences were queried to the National Center for Biotechnology Information database using the Basic Local Alignment Search Tool function, and the best identity matches to a type strain, usually 99.5% or higher, yielded species identification. The queries were made at the time of initial isolation and again during data analyses in 2007 and 2013, particularly for the formerly N asteroides complex organisms in view of taxonomic revisions. The reference Nocardia species and GenBank accession numbers used in this study are listed in ❚Table 1❚. 2, 8, 16, 
Antimicrobial Susceptibility Tests
The in vitro antimicrobial susceptibility of Nocardia strains was tested using the broth dilution method at a large reference laboratory using commercially available kits (Sensititre; Trek Diagnostics, Cleveland, OH) in accordance with the manufacturer's recommendations and published guidelines. 43 Before 2006, antimicrobial susceptibility test data were limited to fewer drugs and strains. Starting from 2006, susceptibility test of a panel of antimicrobials was implemented routinely, which included amikacin, amoxicillinclavulanate, ceftriaxone, ciprofloxacin, clarithromycin, imipenem, linezolid, minocycline, tobramycin, and trimethoprim-sulfamethoxazole (TMP-SMZ).
Clinical Assessment and Definition
Medical records were reviewed for clinical information, including demographics, underlying diseases, evidence and/or manifestation of Nocardia infection, antibiotic treatment, and outcome. Commonly accepted clinical categories were used to group infections into pulmonary, disseminated, localized skin and/or soft tissue, and brain nocardiosis. Given the opportunistic nature of the infections and similarities between Nocardia and nontuberculous mycobacterial infections, we used the American Thoracic Society criteria 44 as well as our previous experience [45] [46] [47] to assess the clinical significance of each isolation episode. Categories included definitive infection, probable infection, and doubtful infection. Objective criteria such as isolation from sterile sources, repeated isolation, recovery from lower respiratory samples with accompanying radiologic evidence of infection, and/or compatible histopathologic findings were emphasized.
Statistical Analysis
When appropriate, statistical analyses were performed by using the Fisher exact test or χ 2 test method.
Results
Prevalence, Species, and Isolation Sources
During the 11 study years, 138 strains of Nocardia consisting of 155 isolates were recovered from 132 patients. The organisms were cultivated from a variety of clinical specimens and media, including routine respiratory culture plates, buffered charcoal yeast extract agar, media for fungi and mycobacteria, and blood culture bottles and plates. The culture recovery generally took 2 to several days for blood and other sterile specimens and for most respiratory specimens. When growth was noted only in media for fungi or mycobacteria, incubation took 1 to 3 weeks. The identification usually took an additional 2 to 3 working days.
❚Table 2❚ shows the species and isolation sources of the 138 Nocardia strains. These strains encompassed 27 Nocardia species, more than half of the approximately 40 medically significant species. No single or a few species predominated, but common species included Nocardia nova (27 strains, 19.6%), Nocardia cyriacigeorgica (25 strains, 18.1%), Nocardia farcinica (19 strains, 13.8%), and Nocardia abscessus (11 strains, 8.0%), together accounting for 59.4% (82 strains). Other relatively common species were Nocardia beijingensis and N veterana. There were 12 rare species with single strains. Twenty of the 27 species have been described since 2000 (Table 1) , and these newer species accounted for 79 strains (57.2%) ( Table 2) .
The respiratory specimens were the most common sources of isolation of these Nocardia strains (101 [73.2%] of 138). There were 13 strains isolated from blood, with four isolated concurrently from other sources as well (three from the respiratory tract and one from the skin). There were 16 strains isolated from the skin tissue (only), including skin abscess and subcutaneous mass. The remaining eight strains were from other sources.
Predilections for tissues were also seen among the species. N nova was the most common species isolated from the bloodstream compared with all other species combined (six of 27 vs seven of 111, P = .021) or other commonly isolated species such as N cyriacigeorgica, N farcinica, N abscessus, N beijingensis, and N veterana combined (six of 27 vs one of 70, P = .002). Thus, N nova likely invades into and survives in the bloodstream. On the other hand, five N farcinica strains were from skin tissue, more often than all other species combined (five of 19 vs 11 of 119, P = .047), suggesting a rather unique dermal tropism. In addition, two of the three strains that were isolated from brain abscess were also N farcinica. Including one blood isolate, these eight N farcinica strains represented deep invasion into tissue (skin and brain) or bloodstream more than all other species combined for this invasiveness (eight of 19 vs 25 of 119, P = .048).
Susceptibility to Antimicrobial Agents
The antimicrobial susceptibility was determined in 117 strains; the results are shown in ❚Table 3❚ and ❚Table 4❚. All tested strains were susceptible to TMP-SMZ (117 tested) and linezolid (108 tested), making these antibiotics the first choices to treat Nocardia infection. Most strains were also susceptible to amikacin (111 [96.5%] of 115).
The overall susceptibility rates to ceftriaxone, tobramycin, and clarithromycin were 66.1% (74 of 112), 57.0% (61 of 107), and 40.4% (46 of 114), respectively. Yet, among the common Nocardia species, the rates varied significantly. For instance, only 11.8% (two of 17) of N farcinica strains were susceptible to ceftriaxone compared with 75.8% (72 of 95) of all other tested species (P < .0001). Similarly, 11.8% (two of 17) of N farcinica strains were susceptible to tobramycin compared with 65.6% (59 of 90) of all other tested species (P < .0001) or, in particular, 100% (23 of 23) of all N cyriacigeorgica strains (P < .0001). All 20 N nova strains were susceptible to clarithromycin, contrasting with none of the 40 strains of N cyriacigeorgica and N farcinica (P < .0001). Therefore, N farcinica is the least susceptible species.
Less susceptible rates were seen for imipenem (49 [ Table 2 and one tested strain of N brasiliensis. mortality within 6 months was 24.2%, illustrating the severity of the underlying cancer. At least five deaths were likely contributed to by the nocardiosis. The most common manifestations were pulmonary infiltrates (62.5%) demonstrated by chest X-ray and/ or computed tomographic scan. Other chest imaging findings included cavity formation (10 cases), pleural effusion (2 cases), pneumothorax (1 case), and "halo sign" (1 case). These findings were not specific for the Nocardia infections. Additional signs and symptoms included shortness of breath (26.5%), cough (25.7%), fever (21.3%), abscess of deep skin and soft tissue (12.5%), and brain abscess (3.7%).
Multiepisodic, Bloodstream, or Disseminated Infections
Four of the 132 patients each experienced two episodes of nocardiosis ❚Table 6❚. They all had hematologic cancers and had received HSCT with corticosteroids (age range, 49-68 years). All these infections resolved on extended or long-term treatment. In one (patient 61 in Table 6 ), the initial episode showed isolation of N farcinica from both skin and the respiratory tract, and 6 months into the treatment with amoxicillin/clavulanate and minocycline, the infection relapsed with the same species isolated from another skin site. In 12 additional months, N beijingensis was isolated from a third skin biopsy specimen to mark the second episode. Eventually, the infections were cured with TMP-SMZ.
In addition to patient 52 in Table 6 with bloodstream (and lung) infection, 11 other patients also had 12 episodes of Nocardia isolated from the bloodstream. All these patients had underlying malignancy, with four also being HSCT recipients. Of all 13 episodes, Nocardia strains were isolated from both CVC and peripheral venous blood simultaneously in five episodes, only CVC blood once, peripheral venous blood only in three, both blood and pulmonary specimen in three, and blood and skin biopsy specimen in one as dissemination (patient 120) ❚Table 7❚. The sources of the bloodstream Nocardia likely originated from CVCs in six, the respiratory tract in three, and uncertain in four. Ten of the episodes were symptomatic, including fever in seven, pulmonary infiltrations (pneumonia) in three, and skin abscess in one (with overlaps). Thus, fever was more common in bloodstream nocardiosis than in other infection sites (seven of 13 vs 22 of 123, P = .003) ( Table 5) .
Of the 13 strains isolated from bloodstream, six were N nova, and the rest were one each of N asteroides, N farcinica, Nocardia harenae, N kruczakiae, Nocardia mikamii, Nocardia pseudobrasiliensis, and Nocardia puvis.
Brain or Skin Involvement
Five (3.8%) of 132 patients had evidence of brain involvement, with three being ascertained by brain biopsy and two being probable through brain imaging studies in addition to disseminated nocardiosis and mental status change. These patients included four men and one woman. Most of them had poor prognosis due to severe underlying cancer and this brain infection. Details of these patients are shown in Table 7 . Two of the three cultured Nocardia species from brain tissue were N farcinica.
Seventeen patients (12.5%) ( Table 2 ), including one in Table 6 and two in Table 7 , manifested abscess of deep skin and soft tissue with isolation of Nocardia. Skin nodules and/or swelling were the most common manifestation of these infections. Extremities were involved in 13 of the 17 Table 2 and one tested strain of N brasiliensis.
Discussion
The present study on the microbiological and clinical features of 138 Nocardia strains from 132 patients likely represents the largest single center study of Nocardia infections. While the study is limited to patients with underlying cancer, the diagnostic consistency and the identification accuracy from the 16S rRNA gene sequencing in a single center are strong points. The results reveal many Nocardia species, most infection types, and a wide range of susceptibility to antimicrobial agents.
Species Distribution
Our 16S gene sequencing method identified 27 Nocardia species, most of the known medically significant Nocardia species. Among the 27 species, common ones included, in descending order, N nova, N cyriacigeorgica, N farcinica, N abscessus, N beijingensis, and N veterana. These findings are consistent with the large number of known Nocardia species and the opportunistic nature of the infection. They also hint at similar environmental distribution or abundance of the common species and similar pathogenicity.
Consistent with taxonomic revisions of previously known "N asteroides" strains, we only noted four strains patients. Histopathology generally showed abscess formation with numerous long bacilli demonstrable on Fite stain, Gomori methenamine silver stain, or tissue Gram stain. These infections were caused by 11 Nocardia species, with N farcinica also being most common.
Infection Without Underlying Cancer
Two patients had probable nocardiosis but without underlying neoplasm. Both had a long history of chronic obstructive pulmonary disease and emphysema. One patient, a 68-year-old man, had a left upper lobe cavity lesion, and histopathology of the lesion done elsewhere showed necrotizing granulomas and possible acid-fast bacilli. Our sputum cultures yielded Mycobacterium simiae, a fungus (sterile hyphae), and Nocardia grenadensis-a species described in 2012 and isolated from the Caribbean sea sand. 42 The patient's lesion improved upon treatment with a few antimicrobials. At the time of occurrence of this case in 2009, this Nocardia species was thought to be N asteroides. The other patient, a 71-year-old man, had a 2-year history of lung nodules without significant constitutional symptoms; our bronchial wash culture grew Nocardia carnea. He was treated with ciprofloxacin and minocycline according to the susceptibility test result as an outpatient. vulnerable to opportunistic pathogens because of the severity of underlying cancer, profound neutropenia, and frequent use of glucocorticoid steroids. They also had more diagnostic procedures, such as bronchoalveolar lavage, to detect various pathogens. In addition, both N farcinica and N brasiliensis, as noted in our study and others, 10, 48, 49 are more pathogenic than other species and may infect relatively healthy hosts. Hence, these species may be more commonly seen in studies from the general population.
Thirteen of the 27 species we recovered have been described in the past 10 years (Table 1) . Our literature searches of these 13 species showed limited numbers of reports of infection due to these organisms. In particular, the case with N grenadensis likely represents the first report of human infection (Table 2) . Geographically, Houston is relatively close to Grenada, where this organism was first isolated. 42 In addition, the four patients with N mikamii, the four with Nocardia aobensis, and the one with Nocardia pneumoniae (Table 2 ) are likely first confirmation of human infections. Before the description of N mikamii in 2010, 41 we had assigned the four strains isolated from the blood, lung biopsy specimen, and bronchoalveolar lavage to Nocardia of N asteroides (sensu stricto). The dwindling number of N asteroides isolates has been the experience of other authors as well. 1, 11 For some reason, we did not recover any Nocardia transvalensis, a species considered common, 1,11 but we did isolate four strains of Nocardia wallacei, a species within the N transvalensis complex and described in 2008. 16 Before that time, we had classified these strains as N asteroides in view of the matches with ATCC 49873, which is now designated as a type strain of N wallacei. 16 All four N wallacei strains were isolated from the lower respiratory tract (Table 2) .
Wauters et al 7 studied species distribution of 86 strains of Nocardia from Belgium as determined by 16S gene sequencing and found that 83 (96%) belonged to six species: N farcinica (44%), N nova (22%), N cyriacigeorgica (15%), N brasiliensis (6.9%), N abscessus (5.8%), and Nocardia paucivorans (2.3%). The common occurrence of N farcinica and N brasiliensis in that study (44 [51.2%] 
Clinical Significance and Sites of Infection
Despite their environmental origin and overall relatively low pathogenicity, isolation of Nocardia species is rarely considered contamination during acquisition of a clinical specimen or laboratory procedure. 10 Applying stringent assessment criteria, including isolation sources, clinical signs and symptoms, radiologic abnormalities, and histopathology, we found that the vast majority (89.1%) of the 136 episodes were definite to probable infections, whereas the 14 doubtful episodes lacked strong evidence of infection.
Among our patients, pulmonary infiltrations were the most frequent and earliest clinical manifestation, leading to workup and diagnosis of nocardiosis. This is consistent with the respiratory tract as the main port of entry of these organisms; it also relates to more diagnostic frequency and approach through radiologic examination and bronchoscopy. Documented fever was infrequent (21.3%), which can be explained by the overall low virulence of Nocardia as well as the poor general condition, profound immunocompromised status, and/or concurrent immunosuppressive medications (corticosteroids or others) of our patients.
Abscess involving skin and deep soft tissue was seen in 12.5% (Table 5) , and 11 various Nocardia species were identified ( Table 2 ). The most frequently involved species was N farcinica, accounting for five (29.4%) of the 17 episodes. N farcinica has a tendency to infect the skin and dissemination, as seen in other series and case reports. 14, 49 Our study has demonstrated such an invasive trait into the skin, brain, and bloodstream in a statistically significant fashion. Therefore, in view of the isolation frequency, the invasiveness, and the least susceptibility to antimicrobials, we consider N farcinica the most pathogenic Nocardia species. Other dermatotropic species, such as N brasiliensis, seen more in other studies, 10, 48 was rare among our patients (Table 2) .
Bloodstream and disseminated infections were seen in 13 (9.6%) episodes and involved eight Nocardia species (Tables  2 and 5) . N nova was most common, causing six of the 13 episodes. These infections and the number of involved species have been infrequently seen in other series. cerradoensis, a species described in 2004 and isolated from soil in Brazil. 50 These two species differ by only a few nucleotides in the 16S gene, 41 and there are no reports of N cerradoensis infection in PubMed. The isolation of N mikamii in the United States and the near full matches of our strains (99.8%-100%) led us to this revision.
Species and Susceptibility
Different Nocardia species may have different susceptibility profiles, which affects initial empiric antimicrobial coverage once a species identification is rendered. 11 Such is true in our study. While all tested strains were susceptible to TMP-SMZ and linezolid and most strains were also susceptible to amikacin, the profiles to other antimicrobials varied remarkably among various species (Tables 3 and 4) . For examples, all 20 N nova strains were susceptible to clarithromycin, all 23 N cyriacigeorgica strains were susceptible to tobramycin, and most N farcinica (11 of 17) were susceptible to amoxicillin/ clavulanate (Tables 3 and 4) . Thus, with species identification reached typically 2 to 3 days by the 16S sequencing after culture recovery, these patterns may guide alternative drug coverage in a timely manner if the first-line drugs are not suitable due to adverse effects or drug reactions. For instance, TMP-SMZ may be undesirable for patients who had HSCT due to its marrow-suppressive potential. Yet HSCT recipients are prone to Nocardia infection, as evidenced by previous studies, 12, 51 as well as this one, in which more than one-third of the patients had HSCT.
Glupcznski et al 52 reported susceptibility studies of 11 antimicrobial agents, determined by the E-test method, against 93 clinical Nocardia strains and 15 type strains of different species. They found that all isolates were susceptible to TMP-SMZ, linezolid, and amikacin, but the susceptibilities to β-lactams, other aminoglycosides, ciprofloxacin, and clarithromycin varied markedly among common species, such as N farcinica (n = 41), N nova (n = 20), and N cyriacigeorgica (n = 13). These findings were similar to ours, which were determined by the Clinical and Laboratory Standards Institute (CLSI)-recommended broth dilution method. Those authors also noted good correlation between the drug resistance patterns and the species identification established by conventional phenotypic tests and 16S gene sequencing.
In a recent multicenter study, Brown-Elliott et al 53 reported that only 2% of 552 Nocardia strains were resistant to SMZ or in combination with TMP. Therefore, susceptibilities to TMP-SMZ, linezolid, and amikacin among various Nocardia species are a consistent finding. In addition, N farcinica has been considered the most resistant Nocardia species. It shows a characteristic resistance to ampicillin, broad-spectrum cephalosporins, clarithromycin, and aminoglycosides except amikacin. 14 Our results are
